Literature DB >> 19184565

VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome.

Shoko Nakayama1, Taiji Yokote, Kichinosuke Kobayashi, Yuji Hirata, Tetsuya Hiraiwa, Izumi Komoto, Kazuho Miyakoshi, Yoshiko Yamakawa, Takayuki Takubo, Motomu Tsuji, Masayuki Imamura, Toshiaki Hanafusa.   

Abstract

We report a case of VIPoma in a 72-year-old female patient who presented with excessive diarrhea, severe hypokalemia, and acidemia. She had been referred to our hospital three times because of severe diarrhea. No primary tumor site was found by conventional techniques, including contrast-enhanced CT and MRI, angiography, endoscopy, and positron emission tomography (PET), but a tumor was subsequently found in the head of the pancreas by octreotide scanning. Her diarrhea diminished dramatically after octreotide treatment, while her diarrhea has ceased without the therapy of octreotide at the first admission in the course of 2 years of her disease. Immunohistochemial analysis of the excised tumor tissue revealed the expression of both vasoactive intestinal peptide (VIP) and VIP and pituitary adenylate cyclase-activating peptide 1 (VPAC1) receptors. This is the first case report of a VIPoma that immunostains for VIP and VPAC1 receptors and indicates that abundant VIP produced by VIPoma might inhibit its growth and reduce VIP secretion via the VPAC1 receptor in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19184565     DOI: 10.1007/s12020-009-9146-6

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  19 in total

1.  Vasoactive intestinal peptide and forskolin regulate proliferation of the HT29 human colon adenocarcinoma cell line.

Authors:  L Gamet; J C Murat; A Remaury; C Remesy; P Valet; H Paris; C Denis-Pouxviel
Journal:  J Cell Physiol       Date:  1992-03       Impact factor: 6.384

2.  Endocrine pancreatic islet disease with diarrhea. Report of a case due to diffuse hyperplasia of nonbeta islet tissue with a review of 54 additional cases.

Authors:  J V Verner; A B Morrison
Journal:  Arch Intern Med       Date:  1974-03

3.  Vasoactive intestinal peptide and watery-diarrhoea syndrome.

Authors:  S R Bloom; J M Polak; A G Pearse
Journal:  Lancet       Date:  1973-07-07       Impact factor: 79.321

4.  Polypeptide with broad biological activity: isolation from small intestine.

Authors:  S I Said; V Mutt
Journal:  Science       Date:  1970-09-18       Impact factor: 47.728

5.  Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions.

Authors:  T B Usdin; T I Bonner; E Mezey
Journal:  Endocrinology       Date:  1994-12       Impact factor: 4.736

6.  Morphologic patterns and diagnostic criteria of VIP-producing endocrine tumors. A histologic, histochemical, ultrastructural, and biochemical study of 32 cases.

Authors:  C Capella; J M Polak; R Buffa; F J Tapia; P Heitz; L Usellini; S R Bloom; E Solcia
Journal:  Cancer       Date:  1983-11-15       Impact factor: 6.860

Review 7.  Receptors for gut regulatory peptides.

Authors:  M Laburthe; A Couvineau; B Amiranoff; T Voisin
Journal:  Baillieres Clin Endocrinol Metab       Date:  1994-01

Review 8.  Liver VIPoma: report of two cases and literature review.

Authors:  C Lundstedt; T Linjawi; T Amin
Journal:  Abdom Imaging       Date:  1994 Sep-Oct

9.  In vitro differentiation of human neuroblastoma cells caused by vasoactive intestinal peptide.

Authors:  J C Pence; N A Shorter
Journal:  Cancer Res       Date:  1990-08-15       Impact factor: 12.701

10.  Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors.

Authors:  I Virgolini; Q Yang; S Li; P Angelberger; N Neuhold; B Niederle; W Scheithauer; P Valent
Journal:  Cancer Res       Date:  1994-02-01       Impact factor: 12.701

View more
  5 in total

Review 1.  Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.

Authors:  Marialuisa Appetecchia; Roberto Baldelli
Journal:  J Exp Clin Cancer Res       Date:  2010-03-02

Review 2.  Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.

Authors:  Terry W Moody; Bernardo Nuche-Berenguer; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-02       Impact factor: 3.243

Review 3.  Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system.

Authors:  Mari Iwasaki; Yasutada Akiba; Jonathan D Kaunitz
Journal:  F1000Res       Date:  2019-09-12

Review 4.  Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy.

Authors:  Yuheng Hu; Zeng Ye; Fei Wang; Yi Qin; Xiaowu Xu; Xianjun Yu; Shunrong Ji
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-19       Impact factor: 5.555

Review 5.  Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives.

Authors:  Roberto Baldelli; A Barnabei; L Rizza; A M Isidori; F Rota; P Di Giacinto; A Paoloni; F Torino; S M Corsello; A Lenzi; M Appetecchia
Journal:  Front Endocrinol (Lausanne)       Date:  2014-02-07       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.